Granules India says 'voluntarily' recalling ranitidine tabs
Granules India has said that it has received multiple queries on the news item for recall of ranitidine by the drug firm. The company is in the process of recall from channel partners and the exact quantities are being estimated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 12, 2020 Category: Pharmaceuticals Source Type: news
Three more heartburn drugs recalled over carcinogen fears
This week, the FDA announced recalls of Zantac generics made by Appco Pharma, Northwind and Mylan's non-ranitidine heartburn drug nizatdine. A California lab thinks heat triggers NDMA's creation. (Source: the Mail online | Health)
Source: the Mail online | Health - January 10, 2020 Category: Consumer Health News Source Type: news
Lab investigates heartburn drug ’s possible cancer link
The popular heartburn drug ranitidine, the generic form of Zantac, was linked to cancer in September, prompting some voluntary recalls of the drug and an investigation by the FDA. A lab in California has also been working to get to the bottom of its potential dangers. First on “CBS This Morning,” Dr. Jon LaPook has a look inside that lab. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 10, 2020 Category: Consumer Health News Source Type: news
Denton Pharma, Inc. dba Northwind Pharmaceuticals Voluntarily Recalls All Unexpired Lots of its Ranitidine Tablets and Ceases Distribution, Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity
Denton Pharma, Inc. dba Northwind Pharmaceuticals, an affiliate of Northwind Pharmaceuticals, LLC ( “Northwind”) today announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300mg, to the consumer level. The recall is in response to the manufacturer’s recall of all un (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Appco Pharma LLC Issues Voluntary Nationwide Recall of Ranitidine Hydrochloride Capsules 150 mg and 300 mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA)
Appco Pharma LLC (Appco) is voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules to the Consumer level. Ranitidine Hydrochloride Capsules are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Supply Disruption Alert Update – Ranitidine: all formulations
The Department of Health and Social Care (DHSC) has issued an update to its previous Supply Disruption Alert. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 23, 2019 Category: Drugs & Pharmacology Source Type: news
